Literature DB >> 12052042

Endocannabinoids in cognition and dependence.

A H Lichtman1, S A Varvel, B R Martin.   

Abstract

Cannabis use is associated with a wide range of pharmacological effects, some of which have potential therapeutic benefit while others result in negative outcomes. Acute cannabinoid intoxication has been well documented to produce deficits in cognitive functioning with concomitant changes in glutamatergic, GABAergic, and cholinergic neurochemical systems in the hippocampus, each of which has been implicated in memory. Additionally, cannabis-dependent individuals abstaining from this drug can undergo a constellation of mild withdrawal effects. The use of the CB(1) cannabinoid receptor antagonist SR141716A and transgenic mice lacking the CB(1) receptor are critical tools for investigating the role of the endocannabinoid system in cognition, drug dependence, and other physiological processes. Converging evidence in which performance in a variety of memory tasks is enhanced following either SR141716A treatment or in CB(1) receptor knockout mice indicates that this system may play an important role in modulating cognition. There are also indications that this system may function to modulate opioid dependence. The purpose of this review is to describe recent advances that have furthered our understanding of the roles that the endocannabinoid system play on both cognition and drug dependence. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052042     DOI: 10.1054/plef.2001.0351

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  41 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 3.  The endocannabinoid system and extinction learning.

Authors:  Beat Lutz
Journal:  Mol Neurobiol       Date:  2007-08-17       Impact factor: 5.590

Review 4.  The acute effects of cannabinoids on memory in humans: a review.

Authors:  Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-09-26       Impact factor: 4.530

5.  Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Authors:  Sara Jane Ward; Sean D McAllister; Rumi Kawamura; Ryuchi Murase; Harshini Neelakantan; Ellen A Walker
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Methods of the pharmacological imaging of the cannabinoid system (PhICS) study: towards understanding the role of the brain endocannabinoid system in human cognition.

Authors:  Hendrika H van Hell; Matthijs G Bossong; Gerry Jager; René S Kahn; Nick F Ramsey
Journal:  Int J Methods Psychiatr Res       Date:  2011-03       Impact factor: 4.035

7.  The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific.

Authors:  Floride Niyuhire; Stephen A Varvel; Andrew J Thorpe; Rene J Stokes; Jenny L Wiley; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2007-01-09       Impact factor: 4.530

8.  Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Authors:  Richard L Suplita; Sarah A Eisenstein; Mark H Neely; Anna M Moise; Andrea G Hohmann
Journal:  Neuropharmacology       Date:  2007-07-19       Impact factor: 5.250

9.  Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans.

Authors:  E L Theunissen; P Heckman; E B de Sousa Fernandes Perna; K P C Kuypers; A Sambeth; A Blokland; J Prickaerts; S W Toennes; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2014-07-08       Impact factor: 4.530

10.  Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.

Authors:  Eleni T Tzavara; Mark Wade; George G Nomikos
Journal:  J Neurosci       Date:  2003-10-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.